Equities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Actions
  • Price (EUR)0.324
  • Today's Change-0.01 / -2.99%
  • Shares traded4.00k
  • 1 Year change+9.46%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,1961,3191,209
Total Receivables, Net625688677
Total Inventory444136
Prepaid expenses4.81215.95
Other current assets, total------
Total current assets1,8692,0691,928
Property, plant & equipment, net520409322
Goodwill, net000
Intangibles, net8697116
Long term investments288306328
Note receivable - long term0.96----
Other long term assets------
Total assets2,8772,9762,781
LIABILITIES
Accounts payable8.057.438.17
Accrued expenses366442397
Notes payable/short-term debt01010
Current portion long-term debt/capital leases6.338.228.68
Other current liabilities, total124114115
Total current liabilities505673528
Total long term debt111623
Total debt1712531
Deferred income tax------
Minority interest1.01(4.08)(3.36)
Other liabilities, total2.153441
Total liabilities519719588
SHAREHOLDERS EQUITY
Common stock104103104
Additional paid-in capital1,2891,2251,265
Retained earnings (accumulated deficit)970934868
Treasury stock - common00(41)
Unrealized gain (loss)(5.61)(5.02)(3.58)
Other equity, total(0.25)(0.18)(0.47)
Total equity2,3582,2572,193
Total liabilities & shareholders' equity2,8772,9762,781
Total common shares outstanding1,0371,0291,032
Treasury shares - common primary issue0011
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.